{
  "extraction_metadata": {
    "timestamp": "2025-10-01T17:11:34.525997",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, disease free survival, radiologic response, pathological response, drop-out rate, recurrence rate, adverse events, intraoperative complications, quality of life, health related quality of life, time to deterioration, time to progression of the tumor",
      "ChunksUsed": 20,
      "ContextTokens": 6574
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, portal vein thrombosis, hepatic arterial thrombosis, tumour necrosis, recurrence, life expectancy, adverse events (general), Karnofsky index, disease-free survival, post operative liver failure, quality of life",
      "ChunksUsed": 20,
      "ContextTokens": 6117
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, radiologic response, pathological response, disease free survival, drop-out rate, recurrence rate, adverse events, intraoperative complications, quality of life, health related quality of life, time to deterioration, time to progression of the tumor, response rates (mRECIST), response rates (RECIST criteria), EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, SF-36, visual analogue scale",
      "ChunksUsed": 20,
      "ContextTokens": 6574
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "improved tumour response, disease-free survival, local tumour control, long-term survival, complication rate, length of admission, perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, irreversible liver failure, tumour necrosis, time to symptom development, quality of life, quality of life (questionnaires), adverse events, limited toxicity, low risk and limited side effects, tumour recurrence, survival after transplantation, recurrence rate after transplantation, risk of bleeding, risk of seeding, diagnostic accuracy, effect of ablative or neoadjuvant therapy (estimated percentage of vital tumour tissue), local control rates, hypertrophy of untreated liver, downstaging to achieve resectability or Milan criteria for transplantation",
      "ChunksUsed": 20,
      "ContextTokens": 7242
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, prognosis (BCLC staging system), therapeutic efficacy, recurrence detection, long-term treatment-related complications",
      "ChunksUsed": 17,
      "ContextTokens": 5125
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "mortality, detection of early hepatocellular carcinoma, bleeding, tumour seeding",
      "ChunksUsed": 6,
      "ContextTokens": 2666
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival, progression-free survival, time-to-progression, objective response rate (RECIST criteria), objective response rate (modified RECIST criteria), local control rates, diarrhoea, hand-foot syndrome, hypertension, decreased appetite, weight loss, fatigue, liver injury, biliary injury, adverse events (general), EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 20,
      "ContextTokens": 7523
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "overall survival, time to disease progression, progression-free survival, tumour response to locoregional therapy, tumour necrosis volume, recurrence rate, disease progression, mortality not related to hepatocellular carcinoma, adverse events, liver failure, portal hypertension, bleeding risk from varicose veins, changes in portal pressure, complication rate, synthetic liver function, survival after liver transplantation, survival after surgical resection, survival after percutaneous local ablative therapy, survival after transarterial chemoembolization, survival after radioembolization, survival after systemic therapy, survival after best supportive therapy, survival after combined locoregional therapies, survival after antiviral therapy, survival after adjuvant therapy, survival after neoadjuvant therapy, survival after down-staging, survival after portal thrombectomy, survival after hepatic resection with portal thrombectomy, survival after supportive therapy, survival after tamoxifen therapy, survival after antiandrogen therapy, survival after chemotherapy, survival after doxorubicin therapy, survival after FOLFOX4 therapy, survival after TACE with drug-eluting beads, survival after TACE alone, survival after radiofrequency ablation, survival after partial hepatectomy, survival after percutaneous alcohol injection, survival after acetic acid injection, survival after transplantation outside Milan criteria, survival after transplantation within Milan criteria",
      "ChunksUsed": 20,
      "ContextTokens": 7216
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survival, response rate, tumour response rate, disease-free survival, local recurrence, local tumor control, bridge to transplant, serious adverse events, adverse events, adverse events (grade 3 and higher), complications, cardiovascular disease, diarrhoea, fatigue, nausea, neutropenia, anaemia, headache, rash, quality of life, Functional Assessment of Cancer Therapy (FACT-G), Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep), EQ-5D, EQ-VAS, adverse events (CTCAE v5.0), overall QoL measured with a validated and reliable instrument, distress (physical and psychological complaints), time from randomisation or initiation of treatment to the occurrence of progression or death (progression-free survival, minimum follow-up of 1 year), overall survival measured from date of randomization until date of death from any cause",
      "ChunksUsed": 20,
      "ContextTokens": 6543
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "progression-free survival, overall survival, response rates (RECIST criteria), response rates (mRECIST), response rates (multiphase computed tomography or magnetic resonance imaging with contrast), perioperative mortality, adverse events (general), adverse events (perioperative), time to progression, completeness of ablation (multiphase computed tomography with contrast), recurrence, annual mortality, bridging to transplantation, reduction of progression, adverse events (radioembolization), adverse events (chemoembolization), adverse events (thermoablation), adverse events (liver resection), adverse events (liver transplantation), adverse events (systemic therapy)",
      "ChunksUsed": 12,
      "ContextTokens": 3639
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "overall survival, survival calculated from the date of diagnosis, five-year survival, one-year survival, response rates (RECIST criteria), response rates (mRECIST criteria), overall response rate (mRECIST), tumour recurrence, time to tumour recurrence, tumour suppression, tumour downstaging, risk of recurrence, risk factors for recurrence (tumour size > 5cm, multiple tumours in the liver, vascular invasion, low differentiation), complications, local recurrence, incomplete tumor destruction, hepatic failure, morbidities, adverse events (general), fatigue, weight loss, loss of appetite, nausea, fever without cause, jaundice, itching, ascites, bone oedema, gastrointestinal bleeding, liver failure, depression, anxiety, stress, EORTC QLQ-C30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, NRS Symptomatic Rating Scale (Symptomatic Validation Instrument), Numeric Rating Scale (NRS) 0-10, radiological assessment of response (DT or MRI with intravenous multiphase contrast), radiological assessment of viable tumor (mRECIST), radiological assessment of viable tumor (LR-TR viable, LR-TR equivocal, LR-TR nonviable), AFP monitoring, quality of life, health status, degree of persistence of symptoms",
      "ChunksUsed": 20,
      "ContextTokens": 7081
    }
  }
}